Jeroen J M A Hendrikx
Overview
Explore the profile of Jeroen J M A Hendrikx including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kicken M, Deenen M, Moes D, Hendrikx J, van den Borne B, Dumoulin D, et al.
Target Oncol
. 2024 Jul;
19(5):779-787.
PMID: 39085452
Background: Atezolizumab is a programmed death-ligand 1 (PD-L1) checkpoint inhibitor for the treatment of different forms of cancer. The subcutaneous formulation of atezolizumab has recently received approval. However, treatment with...
2.
Aalbersberg E, Cao T, Mylvaganan-Young C, Verwoerd D, Peen K, Sonneborn-Bols M, et al.
J Nucl Med Technol
. 2024 Jun;
52(3):267-271.
PMID: 38901965
The radiation exposure of the hands of nuclear medicine laboratory technicians is largely due to the dispensing of radiopharmaceuticals into syringes. To reduce this exposure, a multiradionuclide automatic dispensing system...
3.
Moes D, Hendrikx J, Guchelaar H, Mathijssen R, Bakker J, Dezentje V, et al.
Target Oncol
. 2024 Jun;
19(5):789-796.
PMID: 38890221
Background: The antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer. Its costs may limit patient access...
4.
Siebinga H, de Wit-van der Veen B, de Vries-Huizing D, Vogel W, Hendrikx J, Huitema A
EJNMMI Phys
. 2024 Apr;
11(1):39.
PMID: 38656678
Background: There is an unmet need for prediction of treatment outcome or patient selection for [Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Quantification of the tumor exposure-response...
5.
van Brandwijk E, Aalbersberg E, Hosseini A, Huitema A, Hendrikx J
EJNMMI Radiopharm Chem
. 2024 Apr;
9(1):31.
PMID: 38632189
Background: Steps have been taken by pharmaceutical companies to obtain marketing authorisation of PSMA ligands in the European Union. Since December 2022, Locametz® (PSMA-11, gozetotide) is licensed as kit for...
6.
de Vries-Huizing D, Cheung Z, Hendrikx J, Donswijk M, Versleijen M
Clin Nucl Med
. 2024 Mar;
49(5):454-456.
PMID: 38465961
Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who...
7.
Zuur L, de Barros H, van Oosterom M, Berrens A, Donswijk M, Hendrikx J, et al.
BJU Int
. 2024 Feb;
134(1):81-88.
PMID: 38346924
Objective: To investigate whether combination treatment of prostate-specific membrane antigen (PSMA)-based radioguided surgery (RGS) with short-term androgen deprivation therapy (ADT) improves oncological outcomes in men with oligorecurrent prostate cancer (PCa)...
8.
Siebinga H, de Wit-van der Veen B, Beijnen J, Stokkel M, Dorlo T, Huitema A, et al.
EJNMMI Phys
. 2023 Aug;
10(1):48.
PMID: 37615812
Background: Prediction of [Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [Lu]Lu-HA-DOTATATE. In this study, the population pharmacokinetic (PK)...
9.
Siebinga H, Hendrikx J, Huitema A, de Wit-van der Veen B
EJNMMI Res
. 2023 Jun;
13(1):60.
PMID: 37318681
Background: Folate intake might reduce [Ga]Ga-PSMA-11 uptake in tissues due to a competitive binding to the PSMA receptor. For diagnostic imaging, this could impact decision making, while during radioligand therapy...
10.
Ter Heine R, van den Heuvel M, Piet B, Deenen M, van der Wekken A, Hendriks L, et al.
Target Oncol
. 2023 Apr;
18(3):441-450.
PMID: 37081309
Background: Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide. Objective: We aimed to develop alternative dosing...